Past Symposium - 2022

Immuno-Oncology Symposium

Tuesday, February 1, 2022

9:00 to 16:30 EST

@WesternU_CTCR     #CTCRIO2022

8:45 – 9:00

*all times EST*

Sign In


9:00 – 9:15

Welcome and Opening Remarks


9:00 – 9:15





Saman Maleki, PhD. Conference Chair.

Glenn Bauman, MD. FRCPC. Director – Centre for Translational Cancer Research.

9:15 – 11:30


9:15 - 9:55



“Understanding T-cells immunobiology to improve anti-tumor immunity”.

Pamela Ohashi, PhD. FRSC.

Director, Tumor Immunotherapy Program, Princess Margaret Cancer Centre.

Senior Scientist. Professor, Department of Immunology, University of Toronto.

Canada Research Chair, Tumour Immunity and Immunotherapy.

9:55 - 10:35




“Understanding responses to cancer therapy: the tissue is the issue, the scoop is the poop, and you are what you eat”.

Jennifer Wargo, MD. M.M.Sc.

Professor, Department of Genomic Medicine, Division of Cancer Medicine and Department of Surgical Oncology, Division of Surgery, The University of Texas. MD Anderson Cancer Centre.

10:35 – 10:45

Health Break

10:45- 11:15






“Deciphering CD8+ and CD4+ T cell specificity using novel peptide-HLA dimers”.

Naoto Hirano, MD. PhD.

Associate Director for Research, Tumor Immunotherapy Program, and Senior Scientist, Princess Margaret Cancer Centre, University Health Network. Professor, Department of Immunology, University of Toronto. Senior Investigator, Ontario Institute of Cancer Research. Investigator, BioCanRx.

11:15 - 11:30


Trainee Talks (3)


Lara Gerhardt: “Investigating the role of IL-12 family cytokines in promoting CD39 expression on CD8+ T cells.”

Steve Gameiro:Development of Bioengineered Exosomes for Next-Generation STING Immunotherapies”.

Mary Ibrahim: "The inhibitory NKR-P1B receptor regulates NK cell responses against mammary tumors in mice"



11:30 – 14:15


11:30 - 12:10




"Taking control of innate immunity to ameliorate cancer immunotherapy".

Willem J. M. Mulder, PhD.

Professor, Radiology and Oncological Sciences, and Director, Nanomedicine Program, Icahn School of Medicine, Mount Sinai (NY).

Professor, Precision Medicine, Eindhoven University, Department of Engineering.

12:10 – 12:50


“Engineered antibodies and immunoPET for monitoring responses to immunotherapy”.

Anna Wu, PhD. Chair and Professor, Department of Immunology & Theranostics, and Professor, Department of Radiation Oncology, Beckman Research Institute of City of Hope. Co-Director, Center for Theranostic Studies, City of Hope (Duarte, California). Research Professor, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA. 

12:50 – 13:30

Lunch Break

13:30 – 14:00


“Towards in vivo Immunoscore: Assessing Systemic Immune Response with 18F-AraG”.

Jelena Levi, PhD.

Chief Scientific Officer – CellSight Technologies

14:00 - 14:15


Trainee Talks (3)

John Kelly - "Non-Invasive Monitoring of CRISPR-Cas Edited CAR T Cells with Reporter Gene-Based MRI and PET"

Olivia Sehl – “Imaging immune cells with fluorine-19 MRI”

Sawyer Badiuk - "Glial activation imaging using [18F]-FEPPA PET following cranial irradiation to guide radiotherapy treatments: A pilot study"


14:15 – 16:15


14:15 - 14:55




“Attacking Solid Tumors with T-cell Therapy”.

Patrick Hwu, MD.

President & CEO, Moffitt Cancer Center. Tumor Immunologist, National Cancer Institute.

14:55 – 15:25


“From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy”.

Padmanee Sharma, MD. PhD. Department of Genitourinary Medical Oncology, Division of Cancer Medicine

15:25 – 15:35

Health Break

15:35 – 16:05


“Lack of blocking activity in anti-CTLa-4 antibodies reduces toxity, but not anti-tumor efficacy”.

Erica Stone, PhD.

Vice President, Oncology – GigaGen Inc.

16:05 - 16:20


Trainee Talks (3)

Rober Abdo - “The Spatial Transcriptomic Landscape of Brain Metastases Derived from Non-Small Cell Lung Carcinoma.”

Mara De Martino - “FASN-mediated lipid synthesis hampers anti-cancer immunity of glioblastoma”

Kathy Matuszewska – Fc-3TSR Enhances Delivery and Efficacy of Immunotherapies by Inducing Tumor Vasculature Normalization and Lowering Interstitial Fluid Pressure in a Murine Model of Advanced Ovarian Cancer


Closing Remarks – Saman Maleki, PhD.